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Dlk1 (Pref-1) is a transmembrane and secreted protein, which is
a member of the epidermal growth factor-like family, homo-
logous to Notch/Delta/Serrate. We have found by real-time RT-
PCR that Dlk1 mRNA levels were high in CD34þ cells in 10 of
12 MDS samples compared with CD34þ cells from 11 normals.
Also, Dlk1 mRNA was elevated in mononuclear, low density
bone marrow cells from 11/38 MDS patients, 5/11 AML M6 and
2/4 AML M7 samples. Furthermore, 5/6 erythroleukemia and 2/2
megakaryocytic leukemia cell lines highly expressed Dlk1
mRNA. Levels of Dlk1 mRNA markedly increased during
megakaryocytic differentiation of both CMK megakaryoblasts
as well as normal CD34þ hematopoietic stem cells. High serum
levels of Dlk1 occurred in RA (4/10) and essential thrombo-
cythemia (2/10) patients. Functional studies showed that forced
expression of Dlk1 enhanced proliferation of K562 cells
growing in 1% fetal bovine serum. Analysis of hematopoiesis
of Dlk1 knockout mice suggested that Dlk1 contributed to
granulocyte, megakaryocyte and B-cell clonogenic growth and
was needed for generation of splenic B-cells. In summary, Dlk1
is overexpressed in selected samples of MDS (especially RA
and RAEB) and AML (particularly M6, M7), and it appears to be
associated with normal development of megakaryocytes and B
cells.
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Introduction
Dlk1 (Pref-1, FA1) is a transmembrane and secreted protein.1 It
is a member of the epidermal growth factor-like family with
homologies to Notch/Delta/Serrate, containing a signal peptide,
followed by six epidermal growth factor-like repeats, a
transmembrane domain, and a short intracellular tail.1 Unlike
other delta-family members, Dlk1 lacks the DSL motif, which
may be crucial for the interaction with the Notch family of
molecules,1 suggesting that Dlk1 may exert its activity
independent of the Notch receptors. Dlk1 is present in animals
from birds to mammals and is an imprinted gene.2 The protein is
expressed in a variety of fetal and selected adult tissues and is
thought to participate in embryonic growth,1 hematopoiesis,1
and wound healing.3 It is downregulated during adipocyte
differentiation; addition of recombinant soluble Dlk1 inhibits
adipocyte differentiation of 3T3-L1 cells1 and antisense Dlk1
increases adipocyte differentiation of Balb 3T3.4 In the grand-
ular epithelial cells of the developing pancreas, this protein
decreases in an age-dependent manner.1
Dlk1 is highly expressed in neuroblastoma and small-cell lung
carcinoma and has been suggested to play an important role in
tumorigenesis of these cells.1 Neuroblastoma cell lines treated
with agents that induced differentiation towards the chromaffin
lineage increased their expression of Dlk1, while compounds
that induced differentiation towards the neural phenotype
decreased Dlk1 levels.1
The role of Dlk1 in hematopoiesis has not been clearly
defined.5,6 Stromal cells of the bone marrow can produce Dlk1,
which may promote hematopoiesis.5 Soluble Dlk1-IgG Fc
chimeric protein inhibited the clonal growth of lineage-marker
negative (Lin-) bone marrow cells stimulated by GM-CSF, G-CSF,
or M-CSF in the presence of stem cell factor (SCF).6 It may be
involved in stromal cell-pre-B cell interactions.5 Also, T cells in
the developing thymus express Dlk1 on their cell surface;6 and
in fetal thymus organ cultures, thymocyte cellularity is increased
by exogenous dimeric Dlk1 fusion proteins6 and it is expressed
at higher levels in the thymus during fetal development than in
adult mice.7 Microarray data by others and ourselves found that
Dlk1 mRNA was markedly upregulated in CD34þ hematopietic
marrow stem cells from patients with low-risk MDS compared
with normal individuals.8,9 The present studies show that Dlk1
is dysregulated in selected cases of MDS and AML, and Dlk1
contributes to normal hematopoiesis and B lymphocyte deve-
lopment.
Materials and methods
Cell culture and chemical reagents
Cell lines generously provided include NB4 (acute promyelo-
cytic leukemia (AML-M3) cell line from Dr Lanotte (Hopital
Saint-Louis, Paris, France)); KCL22 (chronic myelogenous
leukemia cell line, Dr I Miyoshi (Kochi University, Kochi,
Japan)); CMK (megakaryocytic leukemia, Dr T Sato (Chiba
University, Chiba, Japan)); HEL, OCIM-I and HEL-R (erythroid
leukemia, Dr T Papayannopoulou (University of Washington,
Seattle, WA, USA)); and TF-1 (erythroid leukemia, Dr K
Kitamura (Tokyo University, Tokyo, Japan)). KG-1 (early AML
cell line) was established by our group. All other cells were
obtained from the American Type Culture Collection (Rockville,
MD, USA) and cultured as described. K562 cells were treated
with either 40 mM hemin (Sigma, St Louis, MO, USA) for 48 h to
induce erythroid differentiation as monitored by hemoglobin
concentrations as described10 or 50 nM 12-O-tetradecanoyl-
phorbol-acetate (TPA) (Sigma, St Louis, MO, USA) for p5 days
to induce megakaryocytic differentiation, monitored by expres-
sion levels of Integrin b3.11
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Brefeldin A and concanamycin A were purchased from Sigma
(St Louis, MO, USA). K562 cells (1 106 cells/ml) were cultured
with either drug at the indicated concentrations for 4 h.
Patient and normal samples
Samples were from 60 newly diagnosed cases of MDS and 31
AML patients. Normal bone marrow CD34þ cells were
obtained from 11 healthy donors. CD34þ cells from MDS and
normal bone marrow were obtained from the mononuclear cell
fraction (Ficoll density separation) followed by immunomag-
netic bead selection with monoclonal murine antihuman CD34
antibodies using the Auto MACs automated separation system
(Miltenyi Biotec, Mo¨nchengladbach, Germany). Yield and
purity of the positively selected CD34þ cells were evaluated
by flow cytometry (FACScan) (Becton Dickinson, Heidelberg,
Germany). Written informed consent was obtained in keeping
with institutional policies.
AML mononuclear cells were separated using gradient
centrifugation with Ficoll-Paque (Pharmacia, Uppsala, Sweden).
At the time of diagnosis, the leukemic cells generally
represented 60–99% of the mononuclear cell fraction.
Real-time RT-PCR assay
Total RNA was isolated from cell lines and clinical samples
using Trizol reagent (Gibco, BRL) according to the standard
protocol. Total RNA (1 mg) was processed directly to cDNA by
reverse transcription with Superscript II (Life Technologies, Inc.)
according to the manufacturer’s protocol in a total volume of
20ml and used for real-time RT-PCR, the details are provided in
Supplementary Information.
Level of mRNA of each gene was evaluated as a ratio to the
level of ribosomal 18S RNA to standardize the quantity of
cDNAs of each sample. Furthermore, levels of Dlk1 mRNA from
the various samples were quantified as relative values to those
present in K562 cells; the relative value of Dlk1 transcripts
in K562 cells as measured by real-time RT-PCR, was regarded
as 100.
ELISA
Using prospectively collected serum samples from 121 normal
individuals, 16 MDS, four myelofibrosis, 10 polycythemia rubra
vera, and 10 essential thrombocythemia patients, serum Dlk1
was quantified using the sandwich ELISA technique based on
polyclonal anti-FA1 (anti-Dlk1) antibodies purified by immuno-
specific affinity chromatography as previously described.12 The
normal values for serum Dlk1 are based on the concentrations in
the serum samples from healthy donors.
Gene expression analysis by oligonucleotide
microarrays
CD34þ bone marrow cells from healthy individuals were
cultured in vitro with TPO to induce megakaryocytic differ-
entiation as previously described.13 The cells were harvested on
days 0, 4, 7, and 11 for expression profiling. Total RNA was
extracted and used for RNA expression analysis using HG-
U133A microarray (Affymetrix Inc.) and analyzed by the
Microarray Analysis Suite 5.0 (Affymetrix, Inc.) and GeneSpring
software version 4.2 (Silicon Genetics, San Carlos, CA, USA) as
previously described.8 The expression level of GAPDH, as
determined by GeneChip assay, was required to be greater than
5000 (raw data) and was measured as ‘present’ (Affymetrix Call)
in all of the samples. The experiments were performed in
triplicates for each of the time points.
Cell transfection and Western blot
The expression vector pcDNA-Dlk1 was constructed by placing
full-length human Dlk1 cDNA into the pcDNA3.1 vector
(Invitrogen). The constructs were transfected into K562 cells
by electroporation and transfectants were selected for their
G418 resistance (800mg/ml). Dlk1 cDNA sequence was
subcloned into the pBI vector (Clontech Laboratories, Palo Alto,
CA, USA) to generate pBI-Dlk1. Empty vector or pBI-Dlk1 were
transfected with pTK-Hyg plasmids into Tet-Off K562 cells.
Transfectants were selected for their resistance to G418 (800 mg/
ml) and hygromycin (200 mg/ml). The Dlk1-expressing clones
were detected by Western blot analysis. Western blot analysis
was performed as previously described.14 Anti-Dlk1 polyclonal
antibody (C-19) (Santa-Cruz, Santa-Cruz, CA, USA) and anti-
GAPDH antibody (Reseach Diagnostic, Flanders, NJ, USA) were
used.
Cell proliferation in liquid culture and clonogenic
assays
Viable cells were counted using the trypan blue dye exclusion
method beginning in 24-well plates at 1 105 cells/well; and
because FBS can contain Dlk1,15 experiments were performed
with both 10 and 1% FBS. Each experiment was performed in
triplicate, and results represent the mean7s.d. of three
experiments.
Dlk1 knockout (KO) mice16 as well as age 6–8-weeks-old
control mice were analyzed. Peripheral blood was obtained by
heart puncture. Mononuclear cells from both bone marrow and
spleens were separated by Ficoll Hypaque density centrifugation
(Amersham Pharmacia, Uppsala, Sweden) and studied for their
myeloid, erythroid, and megakaryocyte clonogenic growth as
recommended by Stem Cell Technologies Inc. (Vancouver, CA,
USA) and as previously reported.5 Details of the cell culture
experiments are provided in Supplementary information.
Flow cytometric analysis
Studies were performed as previously described using B220/
CD45R (RA3-6B2), CD43 (Ly-48), CD4 (L3T4), CD8a (Ly-2),
CD19, murine IgM (R6–60.2), and CD34 (RAM34) (Pharmingen)
monoclonal antibodies conjugated with either fluorescein
isothiocyanate (FITC), phycoerythrin (PE), or peridinin chlor-
ophyll protein (PerCP).
Results
MDS and AML cells overexpress Dlk1
Dlk1 mRNA expression in CD34þ hematopoietic stem cells was
examined in individuals with MDS using real-time RT-PCR.
Level of Dlk1 mRNA in K562 cells was high and was used as an
arbitrary standard (100%) for quantification of Dlk1 mRNA in
other samples. Dlk1 mRNA was nearly undetectable in CD34þ
cells from 11 normal individuals, but levels were high in six of
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seven (85%) RA and four of five (80%) RAEB samples
(Figure 1a). Also, expression of Dlk1 mRNA in light density,
mononuclear bone marrow cells was nearly undetectable in the
eleven normal samples, but was easily measurable in six of 21
RA (28%), 0/4 RARS, 2/13 RAEB (15%), 3/4 RAEB-T (75%), 0/2
CMMoL, 2/4 overt leukemias from MDS (50%), 1/4 AML
M1(25%), 0/2 AML M2, 1/1 AML M3 (100%), 0/4 AML M4,
0/1 AML M4Eo, 0/2 AML M5, 5/11 AML M6 (45%), 2/4 AML M7
(50%), and 1/1(100%) AML M2 transformed from polycythemia
vera (PV) (Figure 1b, these cases are different from those
analyzed in Figure 1a).
Dlk1 mRNA was expressed in erythroid and
megakaryocytic cell lines and levels increased during
normal megakaryocyte differentiation
Human erythroid leukemia cell lines (K562, HEL, HEL-R, TF-1)
and megakaryoblastic leukemia cell lines (CMK and Meg 01)
had high Dlk1 mRNA expression compared to nearly undetect-
able levels in myeloid leukemia lines except KG-1 cells (CD34þ
cells established from an individual with erythroleukemia)
(Figure 1c).
Dlk1 levels markedly decreased (98%) during erythroid
differentiation of K562 cells (Figure 1d). In contrast, Dlk1
expression prominently increased (E40-fold) during megakar-
yocyte differentiation of CMK cells (Figure 1e). Also, as normal
CD34þ hematopoietic stem cells differentiated to megakaryo-
cytes, their levels of Dlk1 mRNA increased (Figure 1f).
Serum levels of Dlk1 are high in some RA patients
Since Dlk1 is both a membrane and secreted protein, we
measured levels of Dlk1 protein in the sera of patients
with MDS, myeloproliferative disorders and normal indivi-
duals (Figure 2). Whereas levels of Dlk1 protein in serum from
almost all normal individuals were less than p50 ng/ml, high
levels were detected in four of 10 patients with RA (40%)
and two of 10 individuals with essential thrombocythemia
(20%) (Figure 2).
Dlk1 is a secreted protein that causes cellular
proliferation of K562 cells
Although K562 cells prominently expressed Dlk1 mRNA
(Figure 1c), low expression of Dlk1 protein was detected
by Western blotting in these cells (data not shown). We
hypothesized that most of the Dlk1 protein generated in
these hematopoietic cells was secreted; and therefore, it was
not detected in the cellular lysates by Western blot. This
was confirmed by treatment of K562 cells with either brefeldin A
or coneanamycin A, which inhibits protein transportation
to the outside of the cells. Levels of Dlk1 protein in K562
cells markedly increased as shown by Western blot (data
not shown).
To examine the effect of Dlk1 on cellular proliferation, we
generated K562 cells stably expressing Dlk1. Three stable clones
expressing Dlk1 and three control clones (Neo) were isolated
(Figure 3a). Each grew similarly in the presence of 10% FBS, but
the Dlk1 expressing clones grew faster than controls in a low
concentration of FBS (1%) (Figure 3a). Further, to confirm the
proliferative activity of Dlk1 in K562 cells, we generated a
tetracycline-inducible clone, pBI Tet Dlk1-cl5. In the absence of
doxycycline, expression of Dlk1 was induced; and withdrawal
of this antibiotic from the culture media, shut off the expression
of Dlk1 (Figure 3b). Induced expression of Dlk1 in K562 cells
again enhanced their proliferation in culture media containing
1% FBS (Figure 3b). To elucidate the mechanisms of the
proliferative activity of Dlk1, we analyzed the levels of cell
cycle regulatory proteins in these cell lines. However, no
difference was detected in levels of Rb, cyclin D1, and p21WAF1
proteins between stable Dlk1 expressing clones of K562 and
control clones (data not shown).
Hematopoiesis in Dlk1 KO mice
In order to understand further the function of Dlk1, hematopoi-
esis was studied in Dlk1 KO mice. Analysis of peripheral blood
of Dlk1 KO mice showed that they had hematocrits (38% vs
44%, KO vs wild type (WT)), white blood cell counts (7.3 vs
8.4 103/ml, KO vs WT) and platelet counts (604 vs 805 103/
ml, KO vs WT); however, P-values were not significantly
different between Dlk1 KO and WT mice. Overall bone marrow
cellularity, differential counts, percentage of red cell precursors
(TER119þ ), and common hematopoietic stem cells (CD34þ )
were similar in the Dlk1 KO and WT mice (data on request).
The progenitor cells in the marrows of Dlk1 KO and WT mice
were assessed by a variety of in vitro clonogenic assays using
growth factors specific for the various cell lineages (see
Materials and methods). Dlk1 KO mice had significantly more
megakaryocyte colony-forming cell (CFU-MK) colonies (mean
53.877.7) than the WT mice (mean 43.273.3) (Po0.001)
(Figure 4a) significantly more granulocyte colony-forming cell
(CFU-G) colonies (mean 32.5710.7) than WT mice (mean
17.575.0) when the marrows were grown with G-CSF alone
(Po0.01) (Figure 4b), and significantly fewer pre-B lymphocyte
colonies (mean 8.675.1) than WT mice (mean 20.776.1)
(Po0.01) (Figure 4c). The number of bone marrow granulocyte-
macrophage precursors (CFU-GM and CFU-M), and erythroid
precursors (BFU-E and CFU-E) were comparable between the
Dlk1 KO and WT mice (data not shown).
Figure 1 Cellular and serum levels of Dlk1 in MDS, AML, myeloproliferative disorders, and myeloid leukemia cell lines. (a) Quantitation of
Dlk1 mRNA in CD34þ hematopietic stem cells from MDS (seven RA and five RAEB patients) and 11 normal individuals measured by real-time RT-
PCR. Levels of Dlk1 are indicated relative to those of K562 cells (relative value of K562, 100). (b) Quantitation of Dlk1 mRNA in the low density,
mononuclear bone marrow cells from 60 MDS (RA, RARS, RAEB, RAEB-T, CMMoL), 31 AML (FAB M1-M7), and 11 healthy volunteers. Levels of
Dlk1 are indicated relative to those of K562 cells (regarded as 100). (c) Quantitation of Dlk1 mRNA in leukemia cell lines. Levels of Dlk1 are
indicated relative to those in K562 cells (regarded as 100). (d) Dlk1 mRNA levels during hemin induced differentiation of K562 cells towards
erythrocytes. Levels of Dlk1 mRNA (upper panel) and hemoglobin (Hgb) concentration in K562 cell lysates confirming that these cells
differentiated towards erythrocytes (lower panel). (Hgb concentration displayed as a % of total cellular protein). (e) Dlk1 mRNA levels as CMK
megakaryoblasts differentiated towards megakaryocytes (TPA, 50 nM) (upper panel). Lower panel shows levels of the megakaryocyte-related
integrin b3 mRNA in CMK, confirming their differentiation toward megakaryocytes. (f) Expression of Dlk1 during normal megakaryocyte
development. CD34þ bone marrow cells from healthy individuals were stimulated in vitro with thrombopoietin to induce megakaryocyte
differentiation. Cells expressing the megakaryocyte cell surface marker, CD61, were isolated and their Dlk1 gene expression was measured by
DNA microarray. (values of Dlk1 expressed as a fraction of GAPDH).
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Effect of recombinant murine (m) Dlk1 protein on clonal
growth of bone marrow cells from Dlk1 KO mice showed
a mean 2376.0 (7s.d.) CFU-G colonies in cultures with
no added mDlk1 and 1476.7 CFU-G colonies with mDlk1
(5 ng/ml) (p¼ 0.048) (Figure 4d). In contrast, a mean 1471.4
pre-B lymphocyte colonies formed from bone marrows
of Dlk1 KO mice; addition of mDlk1 (5 ng/ml) increased the
number of pre-B lymphocyte colonies (2776.3) (Po0.01)
(Figure 4e).
Splenic weights of Dlk1 KO mice were less than those in WT
mice at p8 weeks after birth (Figure 5a). For example, mean
weight of spleens at 6 weeks was 157738 (7s.d.) mg in WT
mice, and 5274.2 mg in Dlk1 KO mice. This difference was
also reflected in splenic sizes (Figure 5b). Splenic sizes and
weights were similar by 16 weeks of age (Figure 5a). Since Dlk1
KO mice had fewer pre-B lymphocyte colonies compared with
WT mice as measured by clonogenic assay of bone marrow
cells, we analyzed B-cell development in the spleens. Although
the difference in the size of spleens between Dlk1 WT and KO
mice was dramatic at 6 weeks, no difference in their lymphoctye
populations was detected between the Dlk1 WT and KO mice
(data not shown). In contrast, whereas the population of B220þ
sIgMþ mature B cells in the spleens of Dlk1 WT mice was
51% at the 16th week, this population was only 33% at the
16th week in the Dlk1 KO mice (Figure 5c). Also, the popula-
tion of B220þ CD43 pre-B lymphocytes increased gradually
(62% at 16 weeks) in WT mice, but this population reached
only 45% at 16 weeks in Dlk1 KO mice (Figure 5d). No
difference was detected in T lymphocyte populations (CD3,
CD4, CD8) between Dlk1 KO and WT mice at any age (data
not shown).
Discussion
In this study, we have found high expression of Dlk1 mRNA in
AML and MDS patients. Interestingly, samples from two patients
with RA and RAEB-T (patients #1 and #2, respectively, in
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Figure 1b) had very high levels of Dlk1 (490% of the level
found in K562 cells) and very low levels of platelets (1.0 and
1.5 104/ml, respectively). Since we have only two cases with
very high levels of Dlk1, we cannot conclude an association
between platelet production and Dlk1 levels, but this possible
association deserves further attention. Our data suggest that
expression of Dlk1 is associated with CD34þ MDS cells, early
erythroid and megakaryoblastic AML cells as well as maturing
normal megakaryocytes. Mechanism of overexpression of Dlk1
mRNA in MDS and AML is unclear and requires further study.
Since Dlk1 is an imprinted gene and Dlk1 is transcribed from
only the paternal allele in normal human,2 loss of imprinting
might occur in selected MDS and AML samples associated with
overexpression of this gene.
Forced expression of Dlk1 in K562 cells enhanced their
proliferation. High expression of Dlk1 in MDS and AML could
provide them with a growth advantage over their normal
hematopoietic counterparts. Mechanism by which Dlk1 en-
hances cellular proliferation is unclear at this time.
Dlk1 KO mice display growth retardation, obesity, blephar-
ophimosis, skeletal malformation, and increased serum lipid
metabolites.16 Similar symptoms occur in humans with maternal
uniparental disomy for chromosome 14 (mUDP14).17 Lack of
Dlk1 may be responsible for some of the symptoms observed in
humans with mUPD14. Dlk1 is an imprinted gene residing on
chromosome 14, and the gene is transcribed only from the
paternal allele. Since patients with mUPD14 disease have
disomy of the maternal allele of chromosome 14, Dlk1 will not
be transcribed in these patients.17 Hematopoietic abnormalities
in individuals with mUDP14 have not been emphasized.
Detailed analysis of hematopoiesis in the Dlk1 KO mice showed
enhanced CFU-G and CFU-MK clonal growth, but decreased
pre-B lymphocyte colony formation. Addition of the soluble
form of Dlk1 to bone marrow cells from Dlk1 KO mice norma-
lized the numbers of CFU-G and pre-B lymphocyte colony
numbers. Despite impairment of clonogenic growth of several
lineages, no significant difference in the peripheral blood cell
counts were detected in the Dlk1 KO mice. A compensating
mechanism might allow hematopoetic normality. Perhaps Dlk1
plays a more important role in embryonic hematopoiesis and
becomes less important with development. By analogy, Notch1
conditional KO mice have a normal peripheral blood profile
except for the T-cell compartment, but closer scrutiny shows
hematopoietic abnormalities of these mice.18
At 6–8 weeks of age, spleens of Dlk1 KO mice were smaller
than those in WT mice. However, no abnormalities of
lymphocyte contents were noted in their spleens. The cause of
these small spleens might be nutritional, since Dlk1 KO mice
have nutritional abnormalities and are small at birth.16 Impair-
ment of B-cell development was noted in spleens of Dlk1 KO
mice at 16 weeks of age; and as mentioned above, their
clonogenic growth of pre-B cells from the bone marrow of Dlk1
was impaired. Our data suggest that Dlk1, especially the soluble
form of Dlk1, may play an important role in B lymphocyte
development. These data buttress the experiments suggesting
that Dlk1 is important for B-cell development in the presence of
IL7 and stromal cells.1
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Figure 4 Hematopoietic clonogenic growth of bone marrow cells
from Dlk1 KO mice. (a–c) Bone marrow cells collected from WT and
Dlk1 KO mice were stimulated with a variety of cytokines in soft gel
plates to examine hematopoiesis in these animals. Data represent
mean colony numbers7s.d. of triplicate cultures containing bone
marrow cells stimulated with appropriate growth factors (details are
provided in Supplementary Information). WT: bone marrow cells from
Dlk1 þ /þ mice. KO: bone marrow cells from Dlk1/ mice. n:
numbers of mice examined; CFU-MK, megakaryocyte colony-forming
cell; CFU-G, granulocyte colony-forming cell. (d, e) Effect of purified
Dlk1 protein on clonogenic growth of hematopoietic cells from Dlk1
WT and KO mice. (d) CFU-G.; (e) pre-B lymphocytes. Mean colony
numbers7s.d. in triplicate cultures containing bone marrow cells from
Dlk1 KO or WT mice stimulated with G-CSF (10 ng/ml) or IL-7 (10 ng/
ml) either with or without mDlk1 protein (5 ng/ml). WT: Dlk1 Wild-
type mice; KO: Dlk1 deletional mice. n numbers of mice examined.
Dlk1 in normal and abnormal hematopoiesis
S Sakajiri et al
1409
Leukemia
High expression of Notch1 is frequently detected in AML;19
and as mentioned, Notch1 conditional KO mice have impaired
T-cell development.20 Taken together, the data suggest that
Notch1 and Dlk1 enhance cellular proliferation and play a role
in lineage-specific development of lymphocytes. Recent data
suggest that Notch1 is also critical for hematopoietic stem cell
generation;21 the role of Dlk1 in normal and abnormal
hematopiesis requires additional studies.
Supplementary Information
Supplementary Information accompanies the paper on the
Leukemia website (http://www.nature.com/leu).
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Figure 5 Spleen sizes in Dlk1 WT and KO mice, and lymphocyte
analysis of spleens from Dlk1 WT and KO mice. (a) Splenic weights
(mean7s.d. of four samples) at different ages from Dlk1 WT and KO
mice. (b) Spleens from the 6-week-old Dlk1 wild type (WT)and Dlk1
deletional (KO) mice. (c, d) Splenocytes from Dlk1 WT and KO mice
were analyzed by two-color flow cytometry using anti-B220 and anti-
sIgM antibodies, or anti-B220 and anti-CD43 antibodies. WT: Dlk1
WT mice; KO: Dlk1 KO mice.
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